ACS Medicinal Chemistry Letters期刊最新论文, 化学/材料, - X-MOL
ACS Medicinal Chemistry Letters | Vol 11, No 10
Our collaborative work with Scott Lokey's Lab at UCSC on PROTAC structure-permeability relationships is now published in ACS Med Chem Lett | Ciulli Laboratory
ACS Med Chem 2011 (2) 919-923
ACS Medicinal Chemistry Letters Referencing Guide · ACS Medicinal Chemistry Letters citation (updated May 21 2023) · Citationsy
ACS Med Chem Lett (@ACSMedChemLett) / Twitter
ACS Med Chem Lett on Twitter: "Our new issue is out with cover art depicting the mechanism of action of vorasidenib (AG-881), a dual inhibitor of mutant IDH1 and 2 for the
Featured Letter in ACS Medicinal Chemistry Letters – NITSCHE LAB
American Chemical Society, Puget Sound Section - Women's History Month. ACS Medicinal Chemistry Letters celebrates women in medicinal chemistry with a Special Issue. https://pubs.acs.org/toc/amclct/11/3 (The cover shows some of the contributors to
ACS Medicinal Chemistry Letters Impact Factor:... | Exaly
A memo about New approach of Drug discovery from ACS medchem letters #memo #journal #RIBOTAC – Is life worth living?
Christine and Sam's CoDEPT manuscript published in ACS Medicinal Chemistry Letters – Owen Lab – University of Utah
A 2020 publication from our PhD student Eleonora Cescon (Cycle 35, Department of Chemical and Pharmaceutical Sciences, UniTS) on ACS Med. Chem. Lett. | Doctoral Programme
ACS MedChem Lett | Cambridge MedChem Consulting
Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C | ACS Medicinal Chemistry Letters
A CIQUS paper among the most read articles in ACS Medicinal Chemistry Letters last month | CiQUS -USC - University of Santiago de Compostela
In press on ACS Med. Chem. Lett.! - SARA (Fortuna) Research Team
ACS Publications - ACS Medicinal Chemistry Letter is soliciting papers on technological advances in medicinal chemistry and drug development. Learn more about the call for papers and be sure to submit your
Discovery and Optimization of Potent, Selective, and in Vivo Efficacious 2-Aryl Benzimidazole BCATm Inhibitors | ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters Template - American Chemical Society
ACS Medicinal Chemistry Letters: Innovations Webinar - YouTube
![Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.6b00242/asset/images/acsmedchemlett.6b00242.social.jpeg_v03 "Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents | ACS Medicinal Chemistry Letters")
Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents | ACS Medicinal Chemistry Letters
ACS MedChem Lett | Cambridge MedChem Consulting
ACS Med Chem Lett (@ACSMedChemLett) / Twitter
Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist | ACS Medicinal Chemistry Letters
Author Guidelines
ACS Med Chem Lett (@ACSMedChemLett) / Twitter
